Yi Lin, M.D., Ph.D., Featured on Mayo Clinic Radio to Explain CAR T-Cell Therapy

On the September 22 broadcast of Mayo Clinic Radio, Yi Lin, M.D., Ph.D., a hematologist at Mayo Clinic and Chair of the Cellular Therapeutics Cross-Disciplinary Group in the Mayo Clinic Cancer Center, explained how chimeric antigen receptor T-cell therapy (CAR T-cell therapy) works and where the research is headed.

In this new cancer treatment, cells in the immune system, known as T cells, are genetically modified to equip them to recognize and destroy cancer cells. CAR T-cell therapy was approved by the U.S. Food and Drug Administration (FDA) last year to treat two types of blood cancer—relapsed B-cell acute lymphoblastic leukemia and relapsed B-cell non-Hodgkin lymphoma. Less than 15% of people who experience recurrence of those cancers respond completely to existing treatments. Up to 90% of people respond to CAR T-cell therapy, with 40% to 50% experiencing remission.

Dr. Lin discussed how CAR T-cell therapy works, new research and developments, and which patients use CAR T-cell therapy and how they recover.

The Podcast
Watch the podcast interview on YouTube.

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.